Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 17 Results

Title
Intervention Indication Therapeutic Area Year Actions
Belzutifan with Lenvatinib in Patients with Advanced Renal Cell Carcinoma Belzutifan (PT2977; MK-6482) , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) Renal cell carcinoma (RCC) Renal Cancer 2024 View  |  Download
Belzutifan for von Hippel-Lindau disease-associated clear cell renal cell carcinoma – first line Belzutifan (PT2977; MK-6482) Renal cell carcinoma (RCC) Genetic Disorders , Oncology , Renal Cancer 2021 View  |  Download
Belzutifan for advanced or metastatic clear cell renal cell carcinoma after 1 therapy Belzutifan (PT2977; MK-6482) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Axitinib for Patients at High Risk of Recurrence of Renal Cell Carcinoma – Adjuvant Axitinib (Inlyta; AG-013736) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
Avelumab in combination with axitinib for advanced or metastatic renal cell carcinoma – first line Avelumab (Bavencio; MSB-0010718C) , Axitinib (Inlyta; AG-013736) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Atezolizumab adjuvant therapy for treating renal cell carcinoma in people at high risk of developing metastasis following nephrectomy Atezolizumab (Tecentriq; MPDL3280A) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications